Rosuvastatin Tablet, Film Coated
Product Images NDC 50090-7430

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 50090-7430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-01 (Figure 1)

This is a statistical analysis comparing the efficacy of RSV and Placebo treatments. The data includes the Hazard Ratio (HR), Confidence Intervals (CI), p-value, and a table with the number at risk and years for each treatment group. The HR for RSV is 0.56 (95% CI 0.46-0.69), with a p-value <0.001, indicating a statistically significant difference between the two treatments. The table shows the number at risk over time for both RSV and Placebo groups.*

FDA Label Image

Figure-02 (Figure 2)

The provided text appears to be data from a study comparing the effects of Rosuvastatin 20 mg and Placebo 20 mg on various cardiovascular endpoints. The study involved 8901 participants and reported outcomes such as the hazard ratio (HR) with confidence intervals and p-values for different endpoints including the primary endpoint, cardiovascular death, nonfatal stroke, nonfatal MI, hospitalized unstable angina, and arterial revascularization. The results suggest significant differences between the treatment groups in terms of these cardiovascular events.*

FDA Label Image

Figure-02 (Figure 3)

FDA Label Image

Label Image (Lbl500907430)

FDA Label Image

Structural Formula (Rosuvastatin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.